MedTrace Logo

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

NCT07104812 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-02-11

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations

Conditions

  • Mild Autonomous Cortisol Secretion
  • Autonomous Cortisol Secretion (ACS)

Interventions

DRUG

Osilodrostat 1 MG

Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks

Sponsors & Collaborators

  • RECORDATI GROUP

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Irina Bancos, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-14
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07104812 on ClinicalTrials.gov